Literature DB >> 2474850

Monoclonal antibodies against measles virus haemagglutinin react with synthetic peptides.

M J Mäkelä1, A A Salmi, E Norrby, T F Wild.   

Abstract

The ability of 17 monoclonal antibodies (MoAb) against measles virus haemagglutinin (MV-H) to bind to 10 selected MV-H-specific synthetic peptides was tested in an enzyme immunoassay (EIA). Three peptides representing residues 126-135 (close to the NH2 terminus), 309-318 (middle), and 587-596 (C-terminal) reacted with MoAb designated 48, I29, and 18, respectively. Binding of MoAb I29 to purified virus was abolished after pre-incubation with the peptide 309-318. Similarly, MoAb 48 did not bind to the virus after absorption with the peptide 126-135. Longer peptides of 19 residues from the regions reacting with the MoAb were also synthesized and tested in EIA. None of the MoAb recognized these longer peptides when the latter were bound as free peptides on solid phase. However, MoAb I29 binding to purified virus was blocked equally well by peptides 304-322 and 309-318. In contrast, peptide 121-139 absorbed the reactivity of the MoAb 48 much more weakly than the shorter peptide 126-135, suggesting that the conformation of the longer peptide in solution is different. To analyse affinities in the antigen-antibody reactions, the plates were washed with buffers of varying pH after absorption of the MoAb to MV or peptides. The MoAb I29 bound both to MV and peptide 309-318 with equal affinity, but MoAb 48 and 18 bound to the peptides 126-135 and 587-596 with lower affinity than to the virus. This study indicates that regions corresponding to amino acids 126-135, 309-318, and 587-596 define antigenic sites of the H protein.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2474850     DOI: 10.1111/j.1365-3083.1989.tb01205.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  6 in total

1.  Sequence and structure alignment of Paramyxoviridae attachment proteins and discovery of enzymatic activity for a morbillivirus hemagglutinin.

Authors:  J P Langedijk; F J Daus; J T van Oirschot
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Identification of immunodominant neutralizing epitopes on the hemagglutinin protein of rinderpest virus.

Authors:  Makoto Sugiyama; Naoto Ito; Nobuyuki Minamoto; Seiichi Tanaka
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

3.  Intracellular processing and antigenic maturation of measles virus hemagglutinin protein.

Authors:  A Hu; J Kövamees; E Norrby
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

4.  Functional and structural characterization of neutralizing epitopes of measles virus hemagglutinin protein.

Authors:  Maino Tahara; Yuri Ito; Melinda A Brindley; Xuemin Ma; Jilan He; Songtao Xu; Hideo Fukuhara; Kouji Sakai; Katsuhiro Komase; Paul A Rota; Richard K Plemper; Katsumi Maenaka; Makoto Takeda
Journal:  J Virol       Date:  2012-10-31       Impact factor: 5.103

5.  Genetic characterization of the hemagglutinin genes of wild-type measles virus circulating in china, 1993-2009.

Authors:  Songtao Xu; Yan Zhang; Zhen Zhu; Chunyu Liu; Naiying Mao; Yixin Ji; Huiling Wang; Xiaohong Jiang; Chongshan Li; Wei Tang; Daxing Feng; Changyin Wang; Lei Zheng; Yue Lei; Hua Ling; Chunfang Zhao; Yan Ma; Jilan He; Yan Wang; Ping Li; Ronghui Guan; Shujie Zhou; Jianhui Zhou; Shuang Wang; Hong Zhang; Huanying Zheng; Leng Liu; Hemuti Ma; Jing Guan; Peishan Lu; Yan Feng; Yanjun Zhang; Shunde Zhou; Ying Xiong; Zhuoma Ba; Hui Chen; Xiuhui Yang; Fang Bo; Yujie Ma; Yong Liang; Yake Lei; Suyi Gu; Wei Liu; Meng Chen; David Featherstone; Youngmee Jee; William J Bellini; Paul A Rota; Wenbo Xu
Journal:  PLoS One       Date:  2013-09-20       Impact factor: 3.240

Review 6.  Measles Virus Hemagglutinin Protein Epitopes: The Basis of Antigenic Stability.

Authors:  Maino Tahara; Jean-Philippe Bürckert; Kazuhiko Kanou; Katsumi Maenaka; Claude P Muller; Makoto Takeda
Journal:  Viruses       Date:  2016-08-02       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.